poster

Adjunctive Brexpiprazole in Patients With Major Depressive Disorder Including in a Subgroup With Energy/Concentration Symptoms: Time to Efficacy Onset

This post hoc pooled analysis of three randomized, fixed-dose, 6-week studies explored time to efficacy onset of adjunctive brexpiprazole 2–3 mg/day in patients with major depressive diso...

10/26/2023

Assessment of Withdrawal Symptoms after Discontinuation of AXS-05 (Dextromethorphan-Bupropion) Treatment: Results from the GEMINI Trial

The GEMINI trial evaluated withdrawal symptoms in MDD patients after a 6-week treatment with AXS-05. Upon discontinuation, symptoms were assessed using the PWC-20. Results showed no signi...

10/26/2023

Adjunctive Brexpiprazole in Patients With Major Depressive Disorder Who Had One Prior Inadequate Antidepressant Including in a Subgroup With Energy/Concentration Symptoms

This post hoc pooled analysis of three randomized, fixed-dose, 6-week studies explored the efficacy of adjunctive brexpiprazole 2–3 mg/day in patients with major depressive disorder who h...

10/26/2023

Association between Anhedonia Severity and Clinical and Humanistic Outcomes Among US Adults with Major Depressive Disorder

This study examined the association of anhedonia severity with health-related outcomes among adults with major depressive disorder (MDD). The results showed that higher anhedonia scores w...

10/26/2023

Adjunctive Cariprazine in Patients With Major Depressive Disorder: A Post Hoc Analysis of Efficacy and Safety by Background Antidepressant Therapy

In this post hoc analysis, data from a phase 3 trial were used to evaluate adjunctive cariprazine versus adjunctive placebo by background ADT in patients with MDD and inadequate response ...

10/26/2023

Agitation Associated with Schizophrenia or Bipolar Disorder: Sublingual Dexmedetomidine Film Efficacy by Baseline Agitation Level

Dexmedetomidine sublingual film reduced agitation symptoms as early as 20 minutes at 180mcg group and 30 minutes at 120mcg, regardless of baseline agitation severity.

10/26/2023

Alternating Hemi-auto-prosopometamorphopsia (Cerebral Asthenopia) of Kith and Kin Mirror Hallucinations.

Prosopometamorphopsia has been noted to be one of the rare symptoms of schizophrenia. Our patient, with schizoaffective disorder, presented with hemi-autoprosopometamorphopsia with half o...

10/26/2023

An Updated Meta-Analysis of the Clinical Utility of Combinatorial Pharmacogenomic Testing for Adult Patients with Depression

This updated meta-analysis investigating the clinical utility of combinatorial pharmacogenomic testing in adult patients (Nf3,532) with depression found that care guided by access to the ...

10/26/2023

Application of AASM Clinical Significance Thresholds to Once-Nightly Sodium Oxybate for Improvement in Narcolepsy Symptoms

Results from the phase 3 REST-ON trial that demonstrated efficacy/safety of extended-release sodium oxybate (once-nightly sodium oxybate [ON-SXB]; LUMRYZ™) were published after the cutoff...

10/26/2023

Are Same Day Clozapine Levels Necessary?

The learning objective is to illustrate clinical scenarios where same-day clozapine blood levels are critical to patient care. Though therapeutic drug monitoring is standard-of-care beca...

10/26/2023

Tracks

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

Major Depressive Disorder

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products